Received 11 million yuan in funding, South Korea plcoskin will develop 3D printed biodegradable PCL breast implants

July 30, 2021, South Korea
biology
Technology company Plcoskin will conduct a study to develop a new type of3D printingbreast
Implants
.

Plcoskin will work with Yonsei University in South Korea and LipoCoat in the Netherlands to complete this research. In the next three years, they will receive about 2 billion won (about 11.26 million yuan) from Eurostar 2
Funding
.

Woo-yeol Baek, CEO of Plcoskin, said: “Through this joint research and development, we will use the lipid film coating technology of LipoCoat in the Netherlands, as well as our3D printingPCL-collagen coating technology to further develop artificial implant manufacturing technology. “

Mastectomy and breast reconstruction

According to the World Health Organization, 2.3 million women worldwide were diagnosed with breast cancer last year. As the most prevalent female cancer in the world, breast cancer causes nearly 700,000 deaths every year.

Most breast cancer patients eventually have to undergo mastectomy. This
Operation
Including partial or complete removal of the affected breast tissue, which means that more and more women are seeking breast reconstruction treatment to replace the lost soft tissue.

Many such breast reconstruction surgeries use soft artificial implants in the shape of the breast, but through3D printingTechnology, the implant can be further customized according to the needs of the patient.

A biodegradable breast implant based on PCL

Plcoskin was founded in 2017, focusing on research and development for regeneration
medicine
Of artificial implants, fillers and prostheses. Just last year, this company was hailed as a “promising overseas bio company” by the Seoul Industrial Promotion Agency, and is currently undergoing domestic approval. They are also preparing to obtain US FDA and European CE MDR approvals next year.

Plcoskin’s latest research project hopes to develop a biodegradable breast implant to3D printingBased on polycaprolactone (PCL) and coated on PCL-collagen and lipid membrane. Using Eurostar 2 funding, Plcoskin has expressed plans to target overseas regenerative medicine markets.

LipoCoat’s contribution to this project is to provide patented bio-coating technology that can improve the infection rate of implants and reduce postoperative discomfort. On the other hand, the Biomedical Engineering Department of Yonsei University also joined in to help carry out laboratory-based research.

Plcoskin also owns its own pharmaceutical cosmetics brand YOULIEF, which currently provides seven different skin care products through multiple online and offline channels. YOULIEF’s product portfolio, including toners and creams, was developed in collaboration with the Johns Hopkins School of Medicine and the Maryland College of Art.

This is certainly not the first time that additive manufacturing has been used in breast cancer treatment. last month,3D printingMachine manufacturer
3D Systems
The company announced that it has reached a joint development agreement with CollPlant, a regenerative medicine company, to develop breast reconstruction treatments.3D bioprintingSoft tissue structure. The soft tissue structure implemented with the breast implant will be used to provide support for the lower breast and increase the overall coverage of the implant.

In addition, researchers at North Carolina State University previously used3D printingThe technology has developed a more comfortable radiation receiving antenna for cancer patients to wear during microwave breast hyperthermia. Compared with mainstream radiotherapy equipment, the flexible receiver they developed is less bulky and can be printed according to the patient’s anatomy.

(Editor in charge: admin)